Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Bioavailability of dietary supplement formulations in healthy volunteers after a single oral dose.
Comparison of the bioavailability of 3 formulations with astaxanthin in healthy volunteers after single dose
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Astaxanthin formulation #1 | Active Comparator | capsules |
|
| Astaxanthin formulation #2 | Active Comparator | tablets |
|
| Astaxanthin formulation #3 | Active Comparator | powder |
|
| Astaxanthin formulations | Experimental | fast condition |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Astaxanthin | Dietary Supplement | an oral dose form |
|
| Measure | Description | Time Frame |
|---|---|---|
| plasma level | astaxanthin in plasma | 0-48 hr |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Are unwilling to follow the procedures of the trial, such as making visits or having their blood drawn.
2. Have unintentionally lost or gained 10 or more kg of body weight in the last 3 months; 3. Have an acute illness (such as a severe cold or flu) or have been hospitalized within the past month for certain conditions; 4. Have severe co-morbid disease including cardiac, pulmonary, renal, hepatic, carotid, peripheral vascular disease, stroke, neurological, clotting disorders or active cancer; 5. Taking chronic drugs which interfere with lipids metabolism (statins or similar) 6. Consume alcohol at an elevated level (Defined as consumption of more than 10 standard alcoholic drinks per week. A standard alcoholic drink is defined as one bottle/can of beer or one glass of wine equals one portion of hard liquor).
7. Consume carotenoids as food supplements. 8. Have a Body Mass Index (BMI) of less than 17 or greater than 35 m/kg2; 9. Have participated in a clinical trial in the past 4 weeks; 10. Have any disease or condition that in the investigator's opinion compromises the integrity of the clinical trial or the safety of the subject; 11. Smokers 12. Pregnant woman
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rafael Bitzur, MD | Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bert W. Strassburger Lipid Center, Sheba Medical Center, | Tel Litwinsky | 52621 | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C005948 | astaxanthine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided